Proteotype Awarded £1.5 Million Grant to Advance Early Cancer Detection with Innovative Enlighten® Test

Proteotype Diagnostics National Institute for Health and Care Research (NIHR) Office for Life Sciences (OLS) United Kingdom England United States of America

is a pioneering diagnostics company dedicated to the development of advanced multi-cancer early detection and personalised medicine tests that measure the host response to tumour development. By leveraging cutting-edge technologies and comprehensive research, Proteotype aims to revolutionise cancer diagnostics and improve early detection, ultimately enhancing patient outcomes and survival rates.

Media contact: [e-mail] 

Email [e-mail] to partner and bring this test to a clinic near you.

Photo - https://mma.prnewswire.com/media/2526337/Proteotype_Diagnostics_Co_founders.jpg

Logo - https://mma.prnewswire.com/media/2526336/Proteotype_Diagnostics_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/proteotype-awarded-1-5-million-grant-to-advance-early-cancer-detection-with-innovative-enlighten-test-302271640.html